TECHNICAL EQUIVALENCE BETWEEN PERKIN-ELMER DRCe AND ELAN 6000 FOR THE ANALYSIS OF 238U IN URINE BIOASSAY SAMPLES by Wong, C T & Collins, L J
UCRL-TR-234270
TECHNICAL EQUIVALENCE BETWEEN
PERKIN-ELMER DRCe AND ELAN 6000
FOR THE ANALYSIS OF 238U IN URINE
BIOASSAY SAMPLES
Carolyn T. Wong, Lori Johnson Collins
September 5, 2007
Disclaimer 
 
 This document was prepared as an account of work sponsored by an agency of the United States 
Government. Neither the United States Government nor the University of California nor any of their 
employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for 
the accuracy, completeness, or usefulness of any information, apparatus, product, or process 
disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any 
specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, 
does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United 
States Government or the University of California. The views and opinions of authors expressed herein 
do not necessarily state or reflect those of the United States Government or the University of California, 
and shall not be used for advertising or product endorsement purposes. 
 
 
 
 
 This work was performed under the auspices of the U.S. Department of Energy by University of 
California, Lawrence Livermore National Laboratory under Contract W-7405-Eng-48. 
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Technical Equivalence Between Perkin-Elmer DRCe and Elan 6000 for the Analysis of 238U 
in Urine Bioassay Samples 
 
 
The LLNL Bioassay Laboratory recently purchased a Perkin-Elmer DRCe ICP-MS (DRCe) to 
replace the existing Perkin-Elmer Elan 6000 ICP-MS (Elan 6000) used for the analysis of 238U in 
urine bioassay samples.  In accordance with section 5.7.2 of DOE-STD-1112-98, “The 
Department of Energy Laboratory Accreditation Program for Radiobioassay”, this document 
demonstrates that the DRCe is technically equivalent to the Elan 6000. 
 
This paper documents:  1) Minor changes made in the procedure to improve the sensitivity; 2) 
Detection limits for the Elan 6000 and the DRCe; 3) Determination of the measurement 
uncertainty for the DRCe; and 4) Comparison of results from the DRCe versus the Elan 6000. 
  
 
Summary of Existing Procedure 
 
A 1 mL aliquot of the sample is transferred to an auto sampler tube.  Nitric acid and 233U (used 
as an internal standard) are added to the samples and the samples are digested in a microwave 
oven. The digested samples are diluted to 10 mL with deionized water and the 238U concentration 
is determined by ICP-MS. 
 
The ICP-MS is calibrated with a series of 238U standards. 233U is used as an internal standard to 
correct for suppression of the signal due to the sample matrix.  The Elan 6000 is run in the peak-
hopping mode with 100 ms dwell times and 50 sweeps.  The total integration time is 5,000 ms.  
The average of two measurements is used for the determination. 
 
 
Modifications to the Procedure to Improve the Sensitivity 
 
In order to reduce the interference from the presence of low levels of 238U and 235U in the 233U 
internal standard, the amount of internal standard used was reduced from 50 uL to 10 uL.  No 
other changes were made in the sample preparation steps. 
 
The existing procedure included calibration standards at 0.005 ug/L to 0.1 ug/L.  In the revised 
procedure, additional standards at 0.0005 ug/L and 0.001 ug/L were added to accommodate 
lower detection limits.  Standards at 0.2 ug/L and 0.5 ug/L were also added to increase the 
dynamic range for the analysis. 
 
The DRCe is run in the peak-hopping mode with 100 ms dwell times and 100 sweeps.  The total 
integration time is 10,000 ms.  The average result for three measurements is used for the 
determination of the final result.  These modifications were made to improve the statistics for the 
analysis. 
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The two instruments are from the same manufacturer and run similar versions of the Perkin-
Elmer Elan software (version 3.3 on the DRCe and 3.0 on the Elan 6000). No changes (other 
than those indicated above) to the operation of the instrument were required.   
 
Modifications to the data transfer process from the DRCe to the LLNL Bioassay Laboratory 
Information Management System (BLIMS) database were made so that instrument data is 
transferred using the local laboratory network rather than using a floppy disk for the data 
transfer.  Modifications were also made in the report to accommodate inclusion of the BLAB 
identification numbers on the ICP-MS reports.   
 
 
Experimental 
 
Blank urine (collected from individuals not occupationally exposed to uranium) were spiked with 
varying amounts of 238U standard and analyzed as samples using the “Determination of Uranium 
in Urine by ICP/MS” procedure.  Eight replicates at each concentration were prepared separately 
by four Bioassay Laboratory Analysts (two replicates per Analyst).  Each series of spikes were 
run as separate runs on the DRCe.  Results for the urine blanks were used to determine the 
detection limit.  Results for the urine blanks and the spikes were used to determine the 
measurement uncertainty.  
 
The results for these analyses are summarized in Table 1.  The seventh result for the 0.010 ug/L 
spike was determined to be an outlier (see Appendix A) and not used in any of the calculations.  
The high bias in the analytical results is due to the presence of natural uranium in the urine used 
to prepare the spikes. 
 
 
Method Detection Limit (MDL99) for the Elan 6000  
 
“Method Development of Uranium Analysis in Urine Matrix by ICP-MS” describes the technical 
basis for the analysis of 238U by ICP-MS on the Elan 6000.  Included in this document is the 
determination of the Method Detection Limit (MDL) and the Reporting Limit (RL).  The MDL99, 
is the minimum concentration of an analyte that in a given matrix can be measured and reported 
with 99% confidence that the analyte concentration is greater than zero.  This value is equivalent 
to the Currie LC at the 99% confidence interval.  Based on the analysis of ten replicate urine 
blank samples, the MDL99 was determined to be 0.002 ug/L.  A Reporting Limit (RL) of 0.01 
ug/L, was derived by multiplying the MDL99 by five. 
 
 
Method Detection Limit (MDL99) for the DRCe 
 
For comparison purposes, the detection limit study described above was repeated on the DRCe.  
The procedure described in the experimental section of this document, which accounts for inter-
analyst and inter-run variability, was used for the determination.  The original determination 
performed on the Elan 6000 was determined based on seven replicates prepared by a single 
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analyst and analyzed in a single run.  We feel that allowing for inter-analyst and inter-run 
variability provides a more realistic determination of the detection limit. 
 
The MDL99 is calculated as follows: 
 
   ))(( 99.0,199 StMDL n−=  (1) 
 
Where: 
  t(n-1,0.99) = Student’s t factor at the 99% confidence limit for n replicate values, and 
 S = the standard deviation of the n replicate values 
 
Based on a standard deviation for the eight replicate samples of 0.0011 ug/L and a Student’s t 
factor of 2.998, the MDL99 is calculated to be 0.0033 ug/L for the DRCe. 
 
 
Minimum Detectable Amount (MDA95) and Decision Level (LC95) based on N13.30 
 
Section 3.4 of N13.30 – “Performance Criteria for Radiobioassay” requires the service 
laboratory to use methodology presented in N13.30 to determine the MDA95 and the LC95.  The 
MDA95 is the minimum detectable amount which provides a <5% probability of a Type I error as 
well as a 5% probability of a Type II error (as opposed to the MDL or LC which only accounts 
for Type I errors).   Additionally Section 4.3.1.1 requires the use of “appropriate blanks” which 
should be in the matrix of interest.  Thus urine blanks were used for the determination rather than 
reagent blanks. 
 
The ICP-MS analysis provides a direct readout of the results in ug/L.  Thus it is similar to the 
Uranium by Kinetic Phosphorescence Analysis and the following calculation is based on the 
example in A.5.13.2 of N13.30.  The MDA95 is calculated as follows: 
 
   ))()(2( 95.0,195 StMDA n−=  (2) 
 
Where: 
  t(n-1,0.95) = Student’s t factor at the 95% confidence limit for n replicate values, and 
 S = the standard deviation of the n replicate values 
 
Note the Student’s t factor is used because only a limited number of replicates were performed 
for the determination.  For large numbers of replicates (well-known background) (2)( t(n-1,0.95)) 
approaches 3.29. 
 
Based on a standard deviation for the eight replicate samples of 0.0011 ug/L and a Student’s t 
factor of 1.895, the MDA95 is calculated to be 0.0042 ug/L. 
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The LC95 is calculated as follows: 
 
   ))(( 95.0,195 StL nC −=  (3) 
 
Where  t(n-1,0.95) and S are defined as above. 
 
Again the Student’s t factor is used because only a limited number of replicates were performed 
for the determination.  For large numbers of replicates (well-known background) t(n-1,0.95) 
approaches 1.645. 
 
Based on a standard deviation for the eight replicate samples of 0.0011 ug/L and a Student’s t 
factor of 1.895, the LC95 is calculated to be 0.0021 ug/L. 
 
 
Required Measurement Quality Objectives (per Internal Dosimetry Requirements) 
 
The “Draft LLNL Technical Basis Manual for Internal Dosimetry” (7/31/07), Appendix B 
includes an expected MDA95 of 0.01 ug/L for the analysis of 238U by ICP-MS.  The MDA95 
determined above clearly meets this expectation. 
 
 
Determination of the Measurement Uncertainty for the DRCe 
 
The combined standard uncertainty (CSU, 1σ) of the analysis is estimated by the standard 
deviation of the replicate analyses.  Based on the data included in Table 1, a plot of the standard 
deviations versus the average values is included in Figure 1.  A linear regression line through all 
of the points yields a line represented by the equation (note the line displayed in Figure 1 does 
not appear linear due to the log scale): 
 
 CSU = 0.0100 (ug/L 238U) + 0.0005 (5) 
R2 = 0.9952 
 
A visual inspection of the plot and the data indicate that the CSU is a constant value of 1% above 
0.1 ug/L of 238U.  Below 0.1 ug/L 238U the regression line underestimates the standard deviations. 
Below 0.1 ug/L of 238U the CSU is best represented by a constant value of 0.0015 (red line on 
Figure 1).  Therefore the CSU shall be calculated as follows: 
 
 ug/L 238U < 0.1 ug/L CSU = 0.0015 ug/L (6) 
 ug/L 238U > 0.1 ug/L CSU = 0.0100 ( ug/L 238U) + 0.0005 (7) 
 
 
Comparison of Results Between the DRCe and the Elan 6000 
 
Three batches of samples containing from 35 to 55 samples were analyzed on both the Elan 6000 
and the DRCe.  Plots of the data comparing the results for the Elan 6000 versus the DRCe are 
included in Figure 2 through Figure 4.  The excellent correlation coefficients (R2 > 0.9979) and 
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slopes of approximately 1 (0.9893 to 1.0076) demonstrate that the results for the two instruments 
are equivalent. 
 
Additional comparisons were performed using performance testing samples previously received 
from ORNL.  Results for these comparisons are summarized in Table 2.  A two-tailed paired t-
test, at the 95% confidence level, analysis of each of the two sets of data give P values of 0.547 
and 0.329 indicating that the results are equivalent. 
 
 
Summary 
 
The information presented in this document clearly demonstrates that the new DRCe meets the 
MQO requirement for the LLNL Internal Dosimetry Program and that analytical results for the 
new instrument (DRCe) are technically equivalent to the old instrument (Elan 6000).  The Lc and 
MDA95 determined for this procedure of 0.0021 ug/L and 0.0042 ug/L are well below the 
expected detection limit of 0.01 ug/L.  Additionally comparisons of the analyses of routine 
samples and performance testing samples on both the DRCe and the Elan 6000 demonstrate 
excellent agreement between the two instruments. 
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Table 1 – Summary of Spiked Urine Blank Samples on the DRCe 
 
Spike Value UB 0.002 0.005 0.010 0.050 0.200 0.500 1.000 2.000 5.000 
 (ug/L) Urine Urine Urine Urine Urine Urine Urine Urine Urine Urine 
 0.0056 0.0106 0.0143 0.0156 0.0552 0.2082 0.5140 1.0121 2.0212 5.0356 
  0.0055 0.0102 0.0098 0.0150 0.0573 0.2091 0.5112 1.0084 2.0204 5.0295 
  0.0073 0.0091 0.0128 0.0168 0.0577 0.2062 0.5146 1.0131 2.0447 5.0444 
  0.0068 0.0087 0.0116 0.0159 0.0569 0.2117 0.5089 1.0202 2.0202 5.0237 
  0.0071 0.0086 0.0115 0.0172 0.0573 0.2080 0.5043 1.0034 1.9904 4.9849 
  0.0071 0.0085 0.0119 0.0169 0.0553 0.2082 0.5004 0.9953 1.9821 4.9098 
  0.0086 0.0107 0.0134 0.034* 0.0597 0.2101 0.5026 1.0020 1.9949 4.9962 
  0.0081 0.0104 0.0138 0.0187 0.0595 0.2086 0.5075 1.0059 1.9995 4.9376 
n 8 8 8 7 8 8 8 8 8 8 
Average 0.0070 0.0096 0.0124 0.0166 0.0574 0.2088 0.5079 1.0076 2.0092 4.9952 
stdev (S) 0.0011 0.0010 0.0015 0.0012 0.0017 0.0016 0.0052 0.0077 0.0208 0.0498 
RSD 15.5% 10.0% 11.9% 7.4% 2.9% 0.8% 1.0% 0.8% 1.0% 1.0% 
 
* Sample result discarded as an outlier (see Appendix A) 
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Table 2 - Comparison of Results for the Elan 6000 versus the DRCe (ORNL Samples) 
 
  BLAB DRCe ELAN 6000 
     DRCe   _    
Elan 6000 
Expected 
(ug/L) 
Observed 
(ug/L) % Bias 
Observed 
(ug/L) % Bias   
3.04 2.980 -2.0% 3.000 -1.3% 0.993 
3.04 2.970 -2.3% 3.010 -1.0% 0.987 
3.04 3.070 1.0% 3.250 6.9% 0.945 
3.04 2.930 -3.6% 2.750 -9.5% 1.065 
3.04 3.040 0.0% 3.160 3.9% 0.962 
3.04 3.010 -1.0% 3.000 -1.3% 1.003 
3.04 3.060 0.7% 3.040 0.0% 1.007 
3.04 3.150 3.6% 3.190 4.9% 0.987 
Average 3.026 -0.5% 3.050 0.3% 0.994 
STDEV 0.069   0.155     
            
1.02 0.937 -8.1% 0.994 -2.5% 0.943 
1.02 0.959 -6.0% 0.968 -5.1% 0.991 
1.02 0.970 -4.9% 1.330 30.4% 0.729 
1.02 0.992 -2.7% 1.100 7.8% 0.902 
1.02 0.971 -4.8% 1.040 2.0% 0.934 
1.02 0.981 -3.8% 1.030 1.0% 0.952 
1.02 0.992 -2.7% 0.866 -15.1% 1.145 
1.02 0.986 -3.3% 0.897 -12.1% 1.099 
Average 0.974 -4.6% 1.028 0.8% 0.962 
STDEV 0.019   0.144     
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Figure 1 – 1σ Error on DRCe 
STDEV of Replicates
y = 0.0100x + 0.0005
R2 = 0.9952
0.0001
0.0010
0.0100
0.1000
0.0010 0.0100 0.1000 1.0000 10.0000
U-238, ug/L
S
T
D
E
V
,
 
u
g
/
L
 
Page 10 of 13 
Figure 2 - Comparison of Results for Elan 6000 versus the DRCe (BLIMS Batch #102506) 
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Figure 3 - Comparison of Results for the Elan 6000 versus the DRCe (BLIMS Batch #102533) 
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Figure 4 - Comparison of Results for the Elan 6000 versus the DRCe (BLIMS Batch #102540) 
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Appendix A - Outlier Test 
 
 
